This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Pulmonary Disease, Chronic Obstructive
and you are
over 40
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of FF/VI 100/25mcg once daily compared with Fluticasone Propionate/Salmeterol 250/50mcg twice daily over a 12-week treatment period in subjects with COPD.

Provided treatments

  • Drug: Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg
  • Drug: Fluticasone Propionate 250mcg / salmeterol 50mcg
  • Drug: Double-dummy placebo
  • Drug: Salbutamol as needed

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01323621. The sponsor of the trial is GlaxoSmithKline and it is looking for 512 volunteers for the current phase.
Official trial title:
A 12-week Study to Evaluate the 24-hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)